𝔖 Bobbio Scriptorium

✦ LIBER ✦

Surgico-therapy for lung cancer at the National Institute for Tuberculosis And Respiratory Diseases, Hanoi, Vietnam

✍ Scribed by Dung, T.T.K; Co, N.V; Anh, P.T.P

Book ID: 118570022
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 110 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80477-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Research resources for tuberculosis at t

Research resources for tuberculosis at the National Institute of Allergy and Infectious Diseases

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 161 KB

During two years 1997–1998 at the Depart

During two years 1997–1998 at the Department of Thoracic Surgery, National Institute for Tuberculosis and Respiratory Diseases (NITRD), 500 in-patients were operated. (40% out of in-patients suffered from lung cancer)

✍ Dung, T.T.K; Co, N.V; Anh, P.T.P 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Patient and Institutional Predictors of

Patient and Institutional Predictors of Trimodality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) in the National Cancer Database

✍ Sher, D.J.; Liptay, M.J.; Fidler, M.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Fatal infection in patients treated for

Fatal infection in patients treated for small cell lung cancer in the Institute of Tuberculosis and Chest Diseases in the years 1980–1994

✍ Remiszewski, P.; Słodkowska, J.; Wiatr, E.; Zych, J.; Radomski, P.; Rowińska-Zak 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Prevalence and Predictors of Neoadjuvant

Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

✍ Sher, David J.; Liptay, Michael J.; Fidler, Mary Jo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB